Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Telehealth-Use Explosion Gets US Senators Crossing Party Lines To Expand Its Practice

Both GOP and Democratic senators praise the health care delivery option, introduce slate of bills to support telemedicine practices

Executive Summary

Many US senators became telemedicine converts during this spring’s COVID-19 trial-by-fire use of the health care delivery option, and avidly pushed bills to back it at a mid-June hearing.

You may also be interested in...



Taskforce On Telehealth Policy Releases Final Recommendations On Safeguarding Virtual Care Beyond Pandemic

The recommendations include lifting geographic restrictions on originating sites, reinstating HIPAA provisions and eliminating restrictions on telehealth across state lines.

US House Panel Passes Telehealth, Counterfeit Device, National Stockpile Bills In Marathon Mark-Up

The House Energy and Commerce Committee swiftly passed three measures impacting medtech companies during a 15 July mark-up session.

Health Care Coalition Asks Congress For Permanent Telemedicine Incentives

A coalition of health groups, medtech and telemedicine associations, and patient groups want the US Congress to permanently enact telehealth use reforms allowed only during the COVID-19 pandemic.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT142322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel